370 related articles for article (PubMed ID: 33895215)
21. Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis.
Jarde A; Lutsiv O; Beyene J; McDonald SD
BJOG; 2019 Apr; 126(5):556-567. PubMed ID: 30480871
[TBL] [Abstract][Full Text] [Related]
22. Withdrawing Approval of Makena - A Proposal from the FDA Center for Drug Evaluation and Research.
Chang CY; Nguyen CP; Wesley B; Guo J; Johnson LL; Joffe HV
N Engl J Med; 2020 Dec; 383(24):e131. PubMed ID: 33140923
[No Abstract] [Full Text] [Related]
23. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
Price JT; Vwalika B; Freeman BL; Cole SR; Mulenga HB; Winston J; Mbewe FM; Chomba E; Mofenson LM; Rouse DJ; Goldenberg RL; Stringer JSA
BMC Pregnancy Childbirth; 2019 Feb; 19(1):81. PubMed ID: 30813934
[TBL] [Abstract][Full Text] [Related]
24. Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate.
Fukuda T; Kyozuka H; Murata T; Yasuda S; Yamaguchi A; Fujimori K
J Obstet Gynaecol Res; 2021 Sep; 47(9):3119-3126. PubMed ID: 34219326
[TBL] [Abstract][Full Text] [Related]
25. Trends in prematurity: what do changes at an urban institution suggest about the public health impact of 17-alpha hydroxyprogesterone caproate?
Bastek JA; Adamczak JE; Hoffman S; Elovitz MA; Srinivas SK
Matern Child Health J; 2012 Apr; 16(3):564-8. PubMed ID: 21484515
[TBL] [Abstract][Full Text] [Related]
26. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
27. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length.
Berghella V; Figueroa D; Szychowski JM; Owen J; Hankins GD; Iams JD; Sheffield JS; Perez-Delboy A; Wing DA; Guzman ER;
Am J Obstet Gynecol; 2010 Apr; 202(4):351.e1-6. PubMed ID: 20350641
[TBL] [Abstract][Full Text] [Related]
28. Nationwide status of progestogen treatment to prevent spontaneous preterm birth: A questionnaire survey for childbirth healthcare facilities in Japan.
Kawabata I; Nagamatsu T; Yoneda S; Oi R; Matsuda Y; Nakai A; Otsuki K
J Obstet Gynaecol Res; 2024 May; 50(5):873-880. PubMed ID: 38369816
[TBL] [Abstract][Full Text] [Related]
29. Effects of progestogens in women with preterm premature rupture of membranes.
Di Sarno R; Raffone A; Saccone G
Minerva Ginecol; 2019 Apr; 71(2):121-124. PubMed ID: 30318880
[TBL] [Abstract][Full Text] [Related]
30. Cellular and biochemical mechanisms, risk factors and management of preterm birth: state of the art.
Vitale SG; Marilli I; Rapisarda AM; Rossetti D; Belluomo G; Iapichino V; Stancanelli F; Cianci A
Minerva Ginecol; 2014 Dec; 66(6):589-95. PubMed ID: 25373016
[TBL] [Abstract][Full Text] [Related]
31. Does adjunctive use of progesterone in women with cerclage improve prevention of preterm birth?
Sinkey RG; Garcia MR; Odibo AO
J Matern Fetal Neonatal Med; 2018 Jan; 31(2):202-208. PubMed ID: 28068860
[TBL] [Abstract][Full Text] [Related]
32. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
[TBL] [Abstract][Full Text] [Related]
33. Practical considerations with 17-Hydroxyprogesterone caproate for preterm birth prevention: does timing of initiation and compliance matter?
Carter EB; Cahill AG; Olsen MA; Macones GA; Tuuli MG; Stout MJ
J Perinatol; 2019 Sep; 39(9):1182-1189. PubMed ID: 31217529
[TBL] [Abstract][Full Text] [Related]
34. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
Awwad J; Usta IM; Ghazeeri G; Yacoub N; Succar J; Hayek S; Saasouh W; Nassar AH
BJOG; 2015 Jan; 122(1):71-9. PubMed ID: 25163819
[TBL] [Abstract][Full Text] [Related]
35. FDA Revokes Approval for Preterm Birth Drug Makena.
Harris E
JAMA; 2023 May; 329(17):1444. PubMed ID: 37043247
[No Abstract] [Full Text] [Related]
36. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM
Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089
[TBL] [Abstract][Full Text] [Related]
37. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
38. The Effect of Intramuscular 17α-Hydroxyprogesterone in Women Screened for Shortened Cervical Length.
Wood SL; Williams BN; Szychowski JM; Owen J
Am J Perinatol; 2020 Jun; 37(7):659-665. PubMed ID: 31756763
[TBL] [Abstract][Full Text] [Related]
39. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
Coleman S; Wallace L; Alexander J; Istwan N
J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
[TBL] [Abstract][Full Text] [Related]
40. Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
Feghali M; Venkataramanan R; Caritis S
Semin Perinatol; 2014 Dec; 38(8):516-22. PubMed ID: 25256193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
